Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women

Journal of Lipid Research

Volumn 41, Issue 3, 2000, Pages 368-375

  Wolfe, Bernard M ^a   Barrett, P H R ^b   Laurier, Lisanne ^a   Huff, Murray W ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cholesterol; Estrogen; LDL; Progesterone; VLDL

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; KINETICS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE;

EID: 0034126872     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Greendale, G. A. 1998. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet. & Gynecol. 92: 982-988.
2. Writing Group for the PEPI Trial. 1996. Effects of hormone therapy on bone mineral density. J. Am. Med. Assoc. 276: 1389-1396.
3. Goldman, L., and A. N. Tosteson. 1991. Uncertainty about postmenopausal estrogen. N. Engl. J. Med. 325: 800-802.
4. Hulley, S., D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280: 605-613.
5. Stampfer, M. J., G. A. Colditz, W. C. Willett, J. E. Manson, B. Rosner, F. E. Speizer, and C. H. Hennekens. 1991. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N. Engl. J. Med. 325: 756-762.
6. Grady, D., S. M. Rubin, D. B. Petitti, C. S. Fox, D. Black, B. Ettinger, V. L. Ernster, and S. R. Cummings. 1992. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Int. Med. 117: 1016-1037.
7. Connelly, P. W., D. R. MacLean, L. Horlick, B. O'Connor, A. Petrasovits, and A. Little. 1992. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian heart health surveys: a profile of cardiovascular risk. Can. Med. Assoc. J. 146 (Special Supplement): 1977-1987.
8. Bengtsson, C., and O. Lindquist. 1978. Coronary heart disease during the menopause. In Coronary Heart Disease in Young Women. M. F. Oliver, editor. Churchill-Livingstone, New York, NY. 234-242.
9. Luciano, A. A. 1992. Hormone replacement therapy in postmenopausal women. Infert. Reprod. Clin. N. Am. 3: 109-127.
10. Mishell, D. R., Jr. 1992. Steroids from menarche to menopause. Introduction. Am. J. Obstet. Gynecol. 166: 1949.
11. Barrett-Connor, E., and T. L. Bush. 1991. Estrogen and coronary heart disease in women. J. Am. Med. Assoc. 265: 1861-1867.
12. Lobo, R. A. 1991. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J. Clin. Endocrinol. Metab. 73: 925-930.
13. Walsh, B. W., I. Schiff, and B. Rosner. 1991. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325: 1196-1204.
14. The Writing Group for the PETI Trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) Trial. J. Am. Med. Assoc. 273: 199-218.
15. Lobo, R. A., J. H. Pickar, R. A. Wild, B. Walsh, and E. Hirvonen. 1994. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet. Gynecol. 84: 987-995.
16. Luciano, A. A., M. J. DeSouza, M. P. Roy, M. J. Schoenfeld, J. C. Nulsen, and C. V. Halvorson. 1993. Evaluation of low-dose estrogen and progestin therapy in postmenopansal women. J. Rep. Med. 38: 207-214.
17. Weinstein, L., C. Bewtra, and J. C. Gallagher. 1990. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am. J. Obstet. Gynecol. 162: 1534-1542.
18. Luciano, A. A., R. N. Turksoy, J. Carleo, and J. W. Hendrix. 1988. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet. Gynecol. 71: 39-13.
19. Prough, S. G., S. Aksel, R. H. Wiebe, and J. Shepherd. 1987. Continuous estrogen/progestin therapy in menopause. Am. J. Obstet. Gynecol. 157: 1449-1453.
20. Weinstein, L. 1987. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet. Gynecol. 69: 929-932.
21. Kable, W. T., J. C. Gallagher, L. Nachtigall, and D. Goldgar. 1990. Lipid changes after hormone replacement therapy for menopause. J. Rep. Med. 35: 512-518.
22. MacLennan, A. H., A. MacLennan, S. Wenzel, H. M. Chambers, and K. Eckert. 1993. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med. J. Aust. 159: 102-106.
23. Wolfe, B. M., and M. W. Huff. 1995. Effects of continuous low-dosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women. Metabolism. 44: 410-417.
24. Moorjani, S., A. Dupont, F. Labrie, B. DeLignieres, L. Cusan, P. Dupont, J. Mailloux, and P-J. Lupien. 1991. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with Urogestan in menopausal women. J. Clin. Endocrinol. Metab. 73: 373-379.
25. Lane, G., M. I. Whitehead, and R. J. B. King. 1982. Effects of oestrogens and progestogens on the histology, ultrastructure, and biochemistry of the postmenopausal endometrium. Int. Med. 2: 13-18.
26. Gambrell, R. D., F. M. Masse, T. A. Castaneda, A. J. Ugenas, C. A. Ricci, and J. M. Wright. 1980. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet. Gynecol. 55: 732-738.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). 1993. J. Am. Med. Assoc. 269: 3015-3023.
28. Canadian Consensus Conference on Cholesterol. 1988. Final Report. Can. Med. Assoc. J. 139 (suppl): 1-8.
29. Jenner, J. L., J. M. Ordovas, S. Lamon-Fava, M. M. Schaefer, P. W. Wilson, W. P. Castelli, and E. J. Schaefer. 1993. Effects of age, sex, and menopausal status on plasma lipoprotein [a] levels. The Framingham Offspring Study. Circulation. 87: 1135-1141.
30. Elliott, W. J. 1994. Dose-response of serum cholesterol during long-term therapy with thiazides. Clin. Pharmacol. Ther. 55: 206 (Abstr.)
31. Havel, R. J., J. P. Kane, E. O. Balasse, N. Segel, and L. V. Basso. 1970. Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans. J. Clin. Invest. 49: 2017-2035.
32. Wolfe, B. M., and M. W. Huff. 1989. Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women. J. Clin. Invest. 83: 40-45.
33. Fidge, N. H., and P. Poulis, 1974. Studies on the radio-iodination of very low density lipoproteins obtained from different mammalian species. Clin. Chim. Acta. 52: 15-26.
34. Reardon, M. F., N. H. Fidge, and P. J. Nestel. 1978. Catabolism of very low density lipoprotein B apoprotein in man. J. Clin. Invest. 61: 850-860.
35. Huff, M. W., D. E. Telford, K. Woodcroft, and W. L. Strong. 1985. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J. Lipid Res. 26: 1175-1186.
36. Phair, R. D., M. G. Hammond, J. A. Bowden, M. Fried, W. R. Fisher, and M. A. Berman. 1975. Preliminary model for human lipoprotein metabolism in hyperlipoproteinemia. Fed. Proc. 34: 2263-2270.
37. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
38. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
39. Huff, M. W., P. M. Giovannetti, and B. M. Wolfe. 1984. Turnover of very low-density lipoprotein-apoprotein B is increased by substitution of soybean protein for meat and dairy protein in the diets of hypercholesterolemic men. Am. J. Clin. Nutr. 39: 888-897.
40. Warnick, G. R., and J. J. Albers. 1978. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J. Lipid Res. 19: 65-76.
41. Snedecor, G. W., and W. G. Cochran. 1967. The comparison of two samples. In Statistical Methods, 6th edition. Iowa State University Press, Ames, IA. 94-97; 114.
42. Kirkwood, B. R. 1988. Non-parametric methods. In Essentials of Medical Statistics. Blackwell Scientific Publications, Oxford. 147-149.
43. Ma, P. T., T. Yamamoto, J. I., Goldstein, and M. S. Brown. 1986. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17α-ethinyl estradiol. Proc. Natl. Acad. Sci. USA. 83: 792-796.
44. Wolfe, B. M., and M. W. Huff. 1993. Effects of low dosage progestin-only administration upon plasma triglycerides and lipoprotein metabolism in postmenopausal women. J. Clin. Invest. 92: 456-461.
45. Reardon, M. F., N. H. Fidge, and P. J. Nestel. 1978. Catabolism of very low density lipoprotein B apoprotein in man. J. Clin. Invest. 61: 850-860.
46. Dentant, T., C. J. Packard, H. Demmelmair, P. Stewart, A. Bedynek, D. Bedford, D. Seidel, and J. Shepherd. 1996. Sensitive methods to study human apoliprotein B metabolism using stable isotope-labeled amino acids. Am. J. Physiol. 270: E1022-E1036.
47. Simons, L. A., S. Balasubramaniam, and J. Holland. 1983. Low density lipoprotein metabolism in the normal to moderately elevated range of plasma Cholesterol: comparisons with familial hypercholesterolemia. J. Lipid Res. 24: 192-199.
48. Grundy, S. M. 1991. Multifactorial etiology of hypercholesterolemia. Arterioscler. Thromb. 11: 1619-1635.
49. Gibbons, W. E., H. L. Judd, A. A. Luciano, L. E. Nachtigall, M. Y. Dawood, K. Burry, H. Ziegl, M. S. LeBoff, G. El-Haij, F. Ogrinc, M. J. Schoenfield, R. P. Buyalos, E. Adashi, and P. Schnatz. 1991. Comparison of sequential versus continuous estrogen/progestin replacement therapy on serum lipid patterns. Am. Soc. Gynecol. Invest. 344: No. 491 (Abstr.)
50. Barrett-Connor, E., S. Sloane, G. Greendale, D. Kritz-Silverstein, M. Espeland, S. R. Johnson, M. Maclawiw, and S. E. Fineberg. 1997. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas. 27: 261-274.
51. Wolfe, B. M., and D. M. Grace. 1979. Norethindrone acetate inhibition of splanchnic triglycride secretion in conscious glucose-fed swine. J. Lipid Res. 20: 175-182.
52. Mishell, D. R. 1989. Estrogen replacement therapy: an overview. Am. J. Obstet. Gynecol. 161: 1825-1827.
53. Wolf, P. H., J. H. Madans, F. F. Finucane, M. Higgins, and J. C. Kleinman. 1991. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am. J. Obstet. Gynecol. 164: 489-494.